Abstract
Background: Leukotrienes are pivotal lipid mediators in various immune and inflammatory reactions. Herein, 5-LO is a validated target. 2-Aminothiazoles, as a privileged structure, implicate known 5-LO inhibitors like ST-1083 (IC50 [polymorphonuclear leukocytes (PMNL)] = 0.68 μM), yet deep structure–activity relationships (SAR) have not been established. Materials & methods: Compounds were synthesized via Hantzsch thiazole synthesis. Inhibitory activities were evaluated using intact PMNL and purified 5-LO together with cytotoxicity measurements in U937 cells. Results: We introduced novel functionalities at 2-, 3-, 4- and 5-position of the 2-aminothiazole scaffold and conducted bioisosteric replacement to optimize the parent scaffold. SARs of the 2-aminothiazole scaffold were deduced and extended primarily for inhibition of the 5-LO enzyme. Conclusion: SAR studies provided at least two optimized leads (ST-1853, ST-1906) with high potency (IC50 [polymorphonuclear leukocytes] = 0.05 μM), specificity and noncytotoxic behavior.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1 . Limiting inflammatory responses during activation of innate immunity. Nat. Immunol. 6(12), 1198–1205 (2005).
- 2 . Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220(4597), 568–575 (1983).
- 3 . Leukotrienes. N. Engl. J. Med. 357(18), 1841–1854 (2007). •• Excellent entry point to leukotriene actions.
- 4 . Arachidonate 5-lipoxygenase. Prostag. Oth. Lipid M. 68–69, 211–234 (2002).
- 5 . Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis. J. Biol. Chem. 279(49), 50639–50642 (2004).
- 6 . Human umbilical vein endothelial cells generate leukotriene C4 via microsomal glutathione S-transferase type 2 and express the CysLT1 receptor. Eur. J. Biochem. 268(9), 2578–2586 (2001). • Outlines the formation of LTC4 via MGST-2.
- 7 . Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog. Lipid Res. 44(2–3), 154–183 (2005).
- 8 . A review on leukotrienes and their receptors with reference to asthma. J. Asthma 50(9), 922–931 (2013).
- 9 . Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J. Biol. Chem. 288(16), 10967–10972 (2013).
- 10 FDA. Approval History. www.fda.gov/.
- 11 . Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int. J. Clin. Pract. 61(4), 663–676 (2007).
- 12 National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma: Full Report 2007. www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf.
- 13 . Recent advances in the search for novel 5-lipoxygenase inhibitors. Basic Clin. Pharmacol. Toxicol. 114(1), 70–77 (2014). •• Current update on recent 5-LO inhibitor drug development.
- 14 . Multiple factors govern the association between pharmacology and toxicity in a class of drugs: toward a unification of class effect terminology. Chem. Res. Toxicol. 24(4), 463–474 (2011).
- 15 A Phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome. Atherosclerosis 240(1), 53–60 (2015).
- 16 . Synthesis and biological evaluation of N-aryl-4-aryl-1,3-thiazole-2-amine derivatives as direct 5-lipoxygenase inhibitors. Chem. Biol. Drug. Des. 80(1), 89–98 (2012).
- 17 Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism. Eur. J. Med. Chem. 84, 302–311 (2014).
- 18 Improved procedures for the preparation of cycloalkyl-, arylalkyl-, and arylthioureas. Synthesis (06), 456–459 (1988). • Insights of thiourea preparation out of any given aniline derivative.
- 19 . Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood 99(3), 1044–1052 (2002).
- 20 . Sequential induction of 5-lipoxygenase gene expression and activity in Mono Mac 6 cells by transforming growth factor beta and 1,25-dihydroxyvitamin D3. Proc. Natl Acad. Sci. USA 92(1), 107–111 (1995).
- 21 . Separation of lipoxins and leukotrienes from human granulocytes by high-performance liquid chromatography with a Radial-Pak cartridge after extraction with an octadecyl reversed-phase column. J. Chromatogr. 493(2), 361–366 (1989).
- 22 Stabilisation and characterisation of the isolated regulatory domain of human 5-lipoxygenase. Biochim. Biophys. Acta 1842(10), 1538–1547 (2014).
- 23 Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Brit. J. Pharmacol. 94(2), 528–539 (1988).
- 24 . Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J. Med. Chem. 56(4), 1363–1388 (2013).
- 25 A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug. Metab. 6(3), 161–225 (2005).
- 26 A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif. Chem. Res. Toxicol. 20(12), 1954–1965 (2007).
- 27 . Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. Chem. Res. Toxicol. 20(12), 1854–1861 (2007).
- 28 . 2-ABT-S-oxide detoxification by glutathione S-transferases A1-1, M1-1 and P1-1: implications for toxicity associated with zileuton. Xenobiotica 39(3), 197–204 (2009).
- 29 . Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105(1), 97–105 (2008).
- 30 High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80(9), 580–604 (2006).
- 31 . Hydroxyurea has the capacity to induce damage to human erythrocytes which can be modified by radical scavengers. Biochem. Biophys. Res. Commun. 120(2), 566–573 (1984).
- 32 . Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J. 17(8), 949–951 (2003).
- 33 . Development of 5-lipoxygenase inhibitors–lessons from cellular enzyme regulation. Biochem. Pharmacol. 70(3), 327–333 (2005). • Review displays pitfalls in 5-LO inhibitor drug development.
- 34 The structure of human 5-lipoxygenase. Science 331(6014), 217–219 (2011). •• First reported crystal structure of human 5-LO.
- 35 . Leukotriene modifiers in the treatment of cardiovascular diseases. J. Leukoc. Biol. 84(6), 1374–1378 (2008).
- 36 5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis. Front. Pharmacol. 1, 143 (2010).
- 37 . The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype. Front. Cell. Neurosci. 8, 436 (2015).